DukeNUS Medical School

CSCB Seminar Series

Title:

"Targeting Protein Methyltransferases for Cancer Therapy."

Abstract:

Altered expression, mutations or translocations of epigenetic modifiers belonging to the protein Methyltransferase family, underlie the etiology of various human diseases, including cancer, and this expanding and diverse group of proteins represent excellent and yet largely unexplored drug targets. The biggest hurdle is to systematically characterize the function of these enzymes in order to prove their direct involvement in driving or sustaining the pathology. To do so, we are combining our skills in biochemistry, molecular- and computational- biology, with expertise in working with mouse models, in order to obtain a detailed understanding of their mechanisms of action, both in normal (development) and disease state.

During my talk I'll give some examples of our recent findings, including the characterization of PRMT5, the major cellular Type II Arginine Methyltransferase, and its involvement in regulating alternative splicing during tumorigenesis.

Date:

10 APRIL 2017 (Monday)

Venue:

Meeting Room 7C, Level 7
Duke-NUS Medical School
8, College Road,
Singapore 169857

Time:

12:00 - 1:00 p.m.

Host:

Sin Tiong ONG,
MA, MRCP
Associate Professor
Programme in Cancer & Stem Cell Biology
Duke-NUS Medical School
Singapore

Speaker:



Ernesto GUCCIONE , Ph.D
Snr. PI, Program Coordinator (Program in Epigenetics and Diseases); Institute of Molecular and Cell Biology (IMCB)
Agency for Science, Technology and Research (A*STAR) Singapore

Dr. GUCCIONE obtained his Master's degree in Medical Biotechnology in 2000 from Bologna University and his PhD in 2004 from the International Center for Genetic Engineering and Biotechnology (ICGEB), Trieste, Italy. He did his postdoctoral work at the European Institute of Oncology (Milan, Italy) where he studied the role of chromatin in defining c-Myc target site recognition. He also identified PRMT6, a member of the Protein Arginine MethylTransferase family, as an important enzyme in controlling transcriptional repression. During his postdoctoral training, he spent four months as an EMBO fellow in the laboratory of J. LaBaer at Harvard Institute of Proteomics. He joined IMCB in 2008 as an Assistant Professor.

No registration is required. All are welcome.
Any enquiries, please contact: Jamie Liew (+65 6516 6954)

CSCB
Cancer and Stem Cell Biology